Canaccord Reiterates Buy Rating on Pacific Biosciences of California (PACB)

March 19, 2026 6:35 AM

Canaccord analyst Kyle Mikson reiterated a Buy rating and $3.00 price target on Pacific Biosciences of California (NASDAQ: PACB).The analyst ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found